Classic Galactosemia Clinical Trial
Official title:
An Open-Label Study to Evaluate the Long-Term Safety and Pharmacodynamic Efficacy of AT-007 in Adult Subjects With Classic Galactosemia (CG)
This study is a 12-month open-label extension (OLE) study of AT-007 in adult subjects with CG who previously participated in Study AT-007-1001 Part D and/or Part D Extension. The study is designed to assess the long-term safety of AT-007 in subjects with CG as well as the pharmacodynamics (PD) (inhibition of galactitol) and PK of AT-007. The effect of 12-month treatment with AT-007 on the levels of galactose and other galactose metabolites in subjects with CG will also be evaluated.
Primary: - To evaluate the long-term safety of 12-month oral administration of AT-007 in adult subjects with Classic Galactosemia (CG) Secondary: - To evaluate the long-term inhibition of galactitol, a biomarker of aldose reductase (AR) activity, induced by 12-month oral administration of AT-007 to adult subjects with CG - To evaluate the pharmacokinetic (PK) parameters of 12-month oral administration of AT-007 in adult subjects with CG Exploratory: - To evaluate the effect of 12-month oral administration of AT-007 on the levels of galactose and its other metabolites in adult subjects with CG - To evaluate the burden of illness (BOI) of adult subjects with CG - To evaluate quality of life (QOL) measures of adult subjects with CG - To evaluate the effect of 12-month oral administration of AT-007 on the BOI and QOL of adult subjects with CG ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT03838016 -
Preventing Speech and Language Disorders in Children With Classic Galactosemia
|
N/A | |
Active, not recruiting |
NCT04902781 -
Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia
|
Phase 2/Phase 3 | |
Completed |
NCT04117711 -
Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia
|
Phase 1/Phase 2 | |
Completed |
NCT03580122 -
The Effect of Arginine on Classic Galactosemia
|
Phase 2 |